<DOC>
	<DOCNO>NCT02614560</DOCNO>
	<brief_summary>This study examine safety anti-leukemic profile SGN-CD33A ( vadastuximab talirine ) patient relapse chemo-resistant AML , give vadastuximab talirine sequence standard treatment plan stem cell transplant , maintenance therapy stem cell transplant . The main purpose study find best dose determine anti-leukemic activity vadastuximab talirine , give either pre- post-allogeneic stem cell transplant ( alloSCT ) adult relapse refractory AML . This determine assess safety tolerability vadastuximab talirine . In addition , pharmacokinetic profile anti-leukemic activity study treatment assess .</brief_summary>
	<brief_title>A Study Vadastuximab Talirine Given Prior After Allogeneic Hematopoietic Stem Cell Transplant AML Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Relapsed/refractory acute myeloid leukemia ( AML ) except acute promyelocytic leukemia Eastern Cooperative Oncology Group status 0 1 Adequate baseline renal hepatic function For Preallo Part A ( stem cell transplant ) : Relapsed refractory AML ( great 5 % blast ) For Preallo Part A ( stem cell transplant ) : Availability HLA match related unrelated donor For Preallo Part A ( stem cell transplant ) : Eligible allogeneic hematopoietic stem cell transplant For Postallo Part B : Transplant must perform active AML ( great 5 % blast ) use conventional condition regimen achieve CR CRi postalloSCT ( ANC great equal 1,000 platelet great equal 50,000 ) For Postallo Part B : Treatment must begin least 60 day , 100 day posttransplant . Inadequate heart function Inadequate lung function Previous central nervous system leukemia Any history another metastatic malignancy Antileukemia treatment within14 day study drug ( hydroxyurea 6mercaptopurine ) , immunosuppressive therapy ( except GVHD treatment/prophylaxis Part B ) , investigational agent For Preallo Part A ( stem cell transplant ) : Partially match donor ( relate unrelated ) umbilical cord blood cell exclude source hematopoietic stem cell For Preallo Part A ( stem cell transplant ) : Prior alloSCT For Postallo Part B : Active GVHD Grade 2 high For Postallo Part B : History venoocclusive disease require defibrotide For Postallo Part B : History Grade 2 high hepatic GVHD For Postallo Part B : Concurrent use corticosteroid equivalent prednisone dose great 0.5 mg/kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>antibody-drug conjugate</keyword>
</DOC>